Compare KTTA & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTTA | ADIL |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 18.5M |
| IPO Year | 2021 | 2017 |
| Metric | KTTA | ADIL |
|---|---|---|
| Price | $0.52 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 214.9K | 51.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $486,559.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3130.37 | N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $2.06 | $7.20 |
| Indicator | KTTA | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 43.02 |
| Support Level | $0.48 | $1.63 |
| Resistance Level | $0.52 | $5.08 |
| Average True Range (ATR) | 0.04 | 0.62 |
| MACD | -0.01 | -0.24 |
| Stochastic Oscillator | 34.21 | 3.45 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.